Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Accumulated Depreciation data on file, last reported at $7.4 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 34.38% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 34.38% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 40.69% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $7.4 million, up from $7.0 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for JANX reached as high as $7.4 million in Q1 2026 and fell as low as $212000.0 in Q1 2022.
• Historically, Accumulated Depreciation has averaged $3.5 million across 5 years, with a median of $3.4 million in 2024.
• Across the five-year window, Accumulated Depreciation jumped 759.09% in 2022 and surged 34.38% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $972000.0 in 2022, then jumped by 199.79% to $2.9 million in 2023, then soared by 69.94% to $5.0 million in 2024, then soared by 40.69% to $7.0 million in 2025, then advanced by 5.53% to $7.4 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $7.4 million in Q1 2026, $7.0 million in Q4 2025, and $6.5 million in Q3 2025.